(Q37944852)

25 August 2017

Radiolabelled mass-balance excretion and metabolism studies in laboratory animals: are they still necessary? (English)

1 reference

25 August 2017

R Scott Obach

1

1 reference

25 August 2017

Angus N Nedderman

series ordinal

2

1 reference

25 August 2017

Dennis A Smith

series ordinal

3

1 reference

25 August 2017

language of work or name

English

0 references

publication date

12 October 2011

1 reference

25 August 2017

1 reference

25 August 2017

42

1 reference

25 August 2017

1

1 reference

25 August 2017

46-56

1 reference

Predicting circulating human metabolites: how good are we?

25 August 2017

1 reference

https://api.crossref.org/works/10.3109%2F00498254.2011.621985

Drug metabolites in safety testing

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00498254.2011.621985

Biotransformation profiling of [(14)C]ixabepilone in human plasma, urine and feces samples using accelerator mass spectrometry (AMS).

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00498254.2011.621985

Assessment of three human in vitro systems in the generation of major human excretory and circulating metabolites

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00498254.2011.621985

Evaluation of preparative high performance liquid chromatography and cryoprobe-nuclear magnetic resonance spectroscopy for the early quantitative estimation of drug metabolites in human plasma.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00498254.2011.621985

A strategy for the risk assessment of human genotoxic metabolites.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00498254.2011.621985

Cyclic metabolites: chemical and biological considerations

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00498254.2011.621985

Nuclear magnetic resonance spectroscopy as a quantitative tool to determine the concentrations of biologically produced metabolites: implications in metabolites in safety testing

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00498254.2011.621985

A simple liquid chromatography-tandem mass spectrometry method to determine relative plasma exposures of drug metabolites across species for metabolite safety assessments

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00498254.2011.621985

Uncommon P450-catalyzed reactions

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00498254.2011.621985

Use of the entero-test, a novel approach for the noninvasive capture of biliary metabolites in dogs

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00498254.2011.621985

Best practices in a tiered approach to metabolite quantification: views and recommendations of the European Bioanalysis Forum.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00498254.2011.621985

Addressing metabolite safety during first-in-man studies using ¹⁴C-labeled drug and accelerator mass spectrometry

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00498254.2011.621985

Which human metabolites have we MIST? Retrospective analysis, practical aspects, and perspectives for metabolite identification and quantification in pharmaceutical development.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00498254.2011.621985

Determination of exposure multiples of human metabolites for MIST assessment in preclinical safety species without using reference standards or radiolabeled compounds

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00498254.2011.621985

From definition to implementation: a cross-industry perspective of past, current and future MIST strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00498254.2011.621985

Analytical strategies for identifying drug metabolites

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00498254.2011.621985

What is the objective of the mass balance study? A retrospective analysis of data in animal and human excretion studies employing radiolabeled drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00498254.2011.621985

Obtaining exposures of metabolites in preclinical species through plasma pooling and quantitative NMR: addressing metabolites in safety testing (MIST) guidance without using radiolabeled compounds and chemically synthesized metabolite standards.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00498254.2011.621985

A holistic strategy for characterizing the safety of metabolites through drug discovery and development

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00498254.2011.621985

Assessment of a micropatterned hepatocyte coculture system to generate major human excretory and circulating drug metabolites

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00498254.2011.621985

Plasma stability-dependent circulation of acyl glucuronide metabolites in humans: how circulating metabolite profiles of muraglitazar and peliglitazar can lead to misleading risk assessment

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00498254.2011.621985

10.3109/00498254.2011.621985

21 January 2018

Identifiers

DOI

1 reference

25 August 2017

1 reference